340B Drug Pricing Program
DEADLINE EXTENDED: Complete 340B survey by June 5.
REMINDER: AHA seeks hospital input on scope of drug company 340B data policy compliance by May 26 deadline.
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug Pricing Program. The letter states:
Complete AHA Survey by May 28 on Drug Company 340B Data Policy Compliance
Please contact your representative about a draft bill that could be considered next week.
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party clearinghouse.
AHA urges Lilly to drop 340B claims-data policy, proposes neutral clearinghouse.
The House Committee on Ways and Means released draft bill text in advance of its planned May 20 markup.
The American Hospital Association expresses concern about Eli Lilly’s January 2026 claims-data policy and invites Lilly to work in good faith with the AHA and our 340B hospital members to find a better path forward than the cycle of escalation that has beset the 340B program in recent years.
AHA pushes back on WSJ anti-340B editorial.